Login / Signup

A recurrent point mutation in PRKCA is a hallmark of chordoid gliomas.

Shai RosenbergIva SimeonovaFranck BielleMaite VerreaultBertille BanceIsabelle Le RouxMailys DaniauArun NadaradjaneVincent GleizeSophie ParisYannick MarieMarine GiryMarc PolivkaDominique Figarella-BrangerMarie-Hélène Aubriot-LortonChiara VillaAlexandre VasiljevicEmmanuèle Lechapt-ZalcmanMichel KalamaridesAriane SharifKarima MokhtariStefano Maria PagnottaAntonio IavaroneAnna LasorellaEmmanuelle HuillardMarc Sanson
Published in: Nature communications (2018)
Chordoid glioma (ChG) is a characteristic, slow growing, and well-circumscribed diencephalic tumor, whose mutational landscape is unknown. Here we report the analysis of 16 ChG by whole-exome and RNA-sequencing. We found that 15 ChG harbor the same PRKCA D463H mutation. PRKCA encodes the Protein kinase C (PKC) isozyme alpha (PKCα) and is mutated in a wide range of human cancers. However the hot spot PRKCA D463H mutation was not described in other tumors. PRKCA D463H is strongly associated with the activation of protein translation initiation (EIF2) pathway. PKCαD463H mRNA levels are more abundant than wild-type PKCα transcripts, while PKCαD463H is less stable than the PCKαWT protein. Compared to PCKαWT, the PKCαD463H protein is depleted from the cell membrane. The PKCαD463H mutant enhances proliferation of astrocytes and tanycytes, the cells of origin of ChG. In conclusion, our study identifies the hallmark mutation for chordoid gliomas and provides mechanistic insights on ChG oncogenesis.
Keyphrases
  • protein kinase
  • wild type
  • high grade
  • binding protein
  • protein protein
  • endothelial cells
  • amino acid
  • signaling pathway
  • gene expression
  • genome wide
  • oxidative stress